| Execution period | Financial Year 2026-27 |
|---|
NSE filing, NSE: GUFICBIO. Summary written from the filing by ALFA Finder's alert engine.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹423.75
- Market cap
- ₹4,249 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 57.9×Sector 46.1×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Business Update
Gufic Biosciences reported a USFDA pre-approval inspection at its Indore facility, concluding October 23, 2026. The inspection produced three Form 483 observations, now being addressed.
Gufic BioSciences Other Announcement
Gufic Biosciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences received a favorable appellate order from the Income Tax Commissioner. This order deletes an income tax demand of Rs. 4.33 Crore.
- Value
- ₹4.33 Cr
Gufic BioSciences Other Announcement
Gufic Biosciences Limited received an overall ESG rating of 62 (Category: Strong) from Crisil for FY 2025-26, assigned independently by the rating agency.
Gufic BioSciences Legal & Regulatory
NSE rejected Gufic Biosciences' waiver application regarding a ₹1.72 lakh penalty for Regulation 17(1A) non-compliance. The company will pay the fine by October 03, 2026.
- Value
- ₹0.02 Cr
Gufic BioSciences Credit Rating
Gufic Biosciences announced that CRISIL Ratings has reaffirmed its credit ratings on the company's total bank loan facilities of ₹516 Crore.
- Value
- ₹516.0 Cr
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.